在日本对碳金脱敏疗法的调查:一个多中心的回顾性研究
Hiroaki Komatsu1, Koji Matsumoto2, Mitsunori Morita2
1Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Tottori, Japan.
Cancer medicine
|March 16, 2024
概括
在日本,卡博普拉丁脱敏疗法有效治疗妇科癌症患者的过敏反应 (HSR). 常见的HSR症状包括红血和,但脱敏治疗的成功率很高.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 对化疗的过敏反应 (HSR) 是癌症治疗中的重大不良事件.
- 碳白是一种广泛使用的化疗剂,对其HSR进行管理对于患者的护理至关重要.
研究的目的:
- 在日本调查卡博普拉丁脱敏治疗的安全性和有效性.
- 建立一种标准化的方法来管理碳金诱导的HSR.
主要方法:
- 在2016年至2020年期间,对136名经过碳波拉丁脱敏治疗的妇科癌症患者进行了回顾性分析.
- 通过在线病例报告表格收集的关于治疗方案和结果的数据.
主要成果:
- 75%的患者成功完成了脱敏治疗.
- 红斑 (68.4%) 和 (52.9%) 是最常见的HSR症状.
- 没有报告死亡病例,也没有确定HSR的风险因素.
结论:
- 在日本人群中,碳白金脱敏疗法表现出高的成功率.
- 红疹和是HSR的关键症状,需要在碳白金脱敏过程中注意.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K


